Targeting Notch in oncology: the path forward

[1]  J. Prensner,et al.  Safety and efficacy of gamma‐secretase inhibitor nirogacestat (PF‐03084014) in desmoid tumor: Report of four pediatric/young adult cases , 2020, Pediatric blood & cancer.

[2]  R. Burger,et al.  Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. , 2020, Gynecologic oncology.

[3]  N. Agarwal,et al.  Therapeutic Targeting of the Notch Pathway in Glioblastoma. , 2019, World neurosurgery.

[4]  Charles C. Hinkley II.  Xenografts , 2019, Moral Conflicts of Organ Retrieval: A Case for Constructive Pluralism.

[5]  A. Neri,et al.  Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance , 2019, Haematologica.

[6]  P. A. Futreal,et al.  Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. , 2019, The Journal of clinical investigation.

[7]  C. Rudin,et al.  Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study , 2019, Clinical Cancer Research.

[8]  Y. Ciribilli,et al.  Dissecting molecular mechanisms of resistance to NOTCH1-targeted therapy in T-cell acute lymphoblastic leukemia xenografts , 2019, Haematologica.

[9]  K. Dou,et al.  Notch signaling via Wnt regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. , 2019, Cancer research.

[10]  M. V. Giuli,et al.  Notch Signaling Activation as a Hallmark for Triple-Negative Breast Cancer Subtype , 2019, Journal of oncology.

[11]  J. Dale,et al.  CDK1 and CDK2 regulate NICD1 turnover and the periodicity of the segmentation clock , 2019, EMBO reports.

[12]  D. Carbone,et al.  DLL3: an emerging target in small cell lung cancer , 2019, Journal of Hematology & Oncology.

[13]  B. de Strooper,et al.  Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition , 2019, Science Translational Medicine.

[14]  J. Kocerha,et al.  The Potential for microRNA Therapeutics and Clinical Research , 2019, Front. Genet..

[15]  Meng-Xi Xiu,et al.  The role of oncogenic Notch2 signaling in cancer: a novel therapeutic target. , 2019, American journal of cancer research.

[16]  J. Sage,et al.  Taking SCLC on a Bad LSD(1) Trip One NOTCH Further. , 2019, Trends in molecular medicine.

[17]  A. Bentivegna,et al.  Role of Notch Signaling Pathway in Glioblastoma Pathogenesis , 2019, Cancers.

[18]  G. Sethi,et al.  FBXW7 in Cancer: What Has Been Unraveled Thus Far? , 2019, Cancers.

[19]  Yinghui Zhu,et al.  Lymphoid enhancer-binding factor-1 promotes stemness and poor differentiation of hepatocellular carcinoma by directly activating the NOTCH pathway , 2019, Oncogene.

[20]  J. Treisman,et al.  Reduced SERCA Function Preferentially Affects Wnt Signaling by Retaining E-Cadherin in the Endoplasmic Reticulum , 2019, Cell reports.

[21]  I. Screpanti,et al.  Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells , 2019, Stem cells international.

[22]  S. Tsunoda,et al.  Age-related remodelling of oesophageal epithelia by mutated cancer drivers , 2019, Nature.

[23]  Daniela Matei,et al.  Targeting Cancer Stemness in the Clinic: From Hype to Hope. , 2019, Cell stem cell.

[24]  David C. Smith,et al.  A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors , 2018, Investigational new drugs.

[25]  J. Crabtree,et al.  Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways , 2018, Front. Oncol..

[26]  S. Deaglio,et al.  The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies , 2018, Front. Oncol..

[27]  L. Boersma,et al.  Moving Breast Cancer Therapy up a Notch , 2018, Front. Oncol..

[28]  Michelle L. Lamb,et al.  Targeting adenosine A2A receptor antagonism for treatment of cancer , 2018, Expert opinion on drug discovery.

[29]  P. Mehlen,et al.  Notch Signaling in the Tumor Microenvironment. , 2018, Cancer cell.

[30]  Guiyu Wang,et al.  Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. , 2018, International journal of biological macromolecules.

[31]  David C. Smith,et al.  A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors , 2018, Investigational New Drugs.

[32]  J. Sarkaria,et al.  NOTCH3 expression is linked to breast cancer seeding and distant metastasis , 2018, Breast cancer research : BCR.

[33]  A. Regev,et al.  Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer. , 2018, Cell reports.

[34]  P. Handford,et al.  Two novel protein O-glucosyltransferases that modify sites distinct from POGLUT1 and affect Notch trafficking and signaling , 2018, Proceedings of the National Academy of Sciences.

[35]  Chien‐Hung Yeh,et al.  FBXW7: a critical tumor suppressor of human cancers , 2018, Molecular Cancer.

[36]  Tian-shu Ren,et al.  A novel inhibitor of ADAM17 sensitizes colorectal cancer cells to 5‐Fluorouracil by reversing Notch and epithelial‐mesenchymal transition in vitro and in vivo , 2018, Cell proliferation.

[37]  C. Giordano,et al.  Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through notch activation in breast cancer cell lines. , 2018, Cancer letters.

[38]  Jiahai Shi,et al.  Histone deacetylase 5 promotes the proliferation and invasion of lung cancer cells. , 2018, Oncology reports.

[39]  L. Dubois,et al.  Drug Resistance in Non-Small Cell Lung Cancer: A Potential for NOTCH Targeting? , 2018, Front. Oncol..

[40]  X. Zhang,et al.  Notch Signaling as a Regulator of the Tumor Immune Response: To Target or Not To Target? , 2018, Front. Immunol..

[41]  E. Rakha,et al.  Inhibition of HER2 Increases JAGGED1-dependent Breast Cancer Stem Cells: Role for Membrane JAGGED1 , 2018, Clinical Cancer Research.

[42]  T. Golde,et al.  Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses , 2018, Front. Immunol..

[43]  S. Winandy,et al.  A Review of Notch Processing With New Insights Into Ligand-Independent Notch Signaling in T-Cells , 2018, Front. Immunol..

[44]  Arielle Rowe,et al.  Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery , 2018, International journal of molecular sciences.

[45]  K. Chu,et al.  MiR-92 suppresses proliferation and induces apoptosis by targeting EP4/Notch1 axis in gastric cancer , 2018, Oncotarget.

[46]  S. Fuqua,et al.  Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival , 2018, Oncogene.

[47]  Han-Xun Wei,et al.  Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer , 2018, International journal of molecular sciences.

[48]  R. Jin,et al.  Lentivirus-mediated overexpression of miR-124 suppresses growth and invasion by targeting JAG1 and EZH2 in gastric cancer. , 2018, Oncology letters.

[49]  T. Koyano,et al.  The Notch Inhibitors Isolated from Nerium indicum. , 2018, Journal of natural products.

[50]  F. Sotgia,et al.  Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism. , 2018, Biochimica et biophysica acta. Bioenergetics.

[51]  T. Koyano,et al.  The Notch inhibitor cowanin accelerates nicastrin degradation , 2018, Scientific Reports.

[52]  L. Mureşan,et al.  Activation of the Notch Signaling Pathway In Vivo Elicits Changes in CSL Nuclear Dynamics , 2018, Developmental cell.

[53]  R. Kageyama,et al.  Small-molecule screening yields a compound that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone , 2018, The Journal of Biological Chemistry.

[54]  W. Wong,et al.  Engineering Axl specific CAR and SynNotch receptor for cancer therapy , 2018, Scientific Reports.

[55]  W. Ge,et al.  Effect of lenalidomide on the human gastric cancer cell line SGC7901/vincristine Notch signaling , 2018, Journal of cancer research and therapeutics.

[56]  J. Califano,et al.  The NOTCH Pathway in Head and Neck Squamous Cell Carcinoma , 2018, Journal of dental research.

[57]  Lijun Tang,et al.  Differentiation-inducing therapeutic effect of Notch inhibition in reversing malignant transformation of liver normal stem cells via MET , 2018, Oncotarget.

[58]  S. Winandy,et al.  Novel TCR-Mediated Mechanisms of Notch Activation and Signaling , 2018, The Journal of Immunology.

[59]  S. Zacchigna,et al.  Taming the Notch Transcriptional Regulator for Cancer Therapy , 2018, Molecules.

[60]  K. Yasutomo,et al.  Regulation of CD8+ T Cells and Antitumor Immunity by Notch Signaling , 2018, Front. Immunol..

[61]  Jennifer S. Yu,et al.  Hypoxic Induction of Vasorin Regulates Notch1 Turnover to Maintain Glioma Stem-like Cells. , 2018, Cell stem cell.

[62]  Yi Ren,et al.  Paeoniflorin influences breast cancer cell proliferation and invasion via inhibition of the Notch‑1 signaling pathway. , 2017, Molecular medicine reports.

[63]  K. Garcia,et al.  Inhibition of Delta-induced Notch signaling using fucose analogs , 2017, Nature chemical biology.

[64]  A. Ferrando,et al.  Leukemia-specific delivery of mutant NOTCH1 targeted therapy , 2018, The Journal of experimental medicine.

[65]  J. Soria,et al.  First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  B. Osborne,et al.  Notch and T Cell Function - A Complex Tale. , 2018, Advances in experimental medicine and biology.

[67]  Xinhua Sun,et al.  Baicalein suppresses non small cell lung cancer cell proliferation, invasion and Notch signaling pathway. , 2018, Cancer biomarkers : section A of Disease markers.

[68]  Zhi Wei,et al.  Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. , 2018, Cancer discovery.

[69]  A. Jimeno,et al.  Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor , 2018, Annals of Surgical Oncology.

[70]  Yibin Kang,et al.  Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. , 2017, Cancer cell.

[71]  A. Neri,et al.  Identification of small molecules uncoupling the Notch::Jagged interaction through an integrated high-throughput screening , 2017, PloS one.

[72]  M. Moss,et al.  Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation , 2017, Mediators of inflammation.

[73]  J. Rosenfeld,et al.  Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma , 2017, Molecular Cancer Therapeutics.

[74]  H. Clevers,et al.  Cancer stem cells revisited , 2017, Nature Medicine.

[75]  H. Berman,et al.  Notch Shapes the Innate Immunophenotype in Breast Cancer. , 2017, Cancer discovery.

[76]  Ling Yu,et al.  The synergistic antitumor effect of cinobufagin and cisplatin in human osteosarcoma cell line in vitro and in vivo , 2017, Oncotarget.

[77]  R. Adams,et al.  Dll4 and Notch signalling couples sprouting angiogenesis and artery formation , 2017, Nature Cell Biology.

[78]  R. Tanzi,et al.  Pharmacological and Toxicological Properties of the Potent Oral γ-Secretase Modulator BPN-15606 , 2017, The Journal of Pharmacology and Experimental Therapeutics.

[79]  T. Golde,et al.  γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct , 2017, EMBO molecular medicine.

[80]  M. Memo,et al.  Notch ligand Delta-like 1 as a novel molecular target in childhood neuroblastoma , 2017, BMC Cancer.

[81]  D. Sprinzak,et al.  The Canonical Notch Signaling Pathway: Structural and Biochemical Insights into Shape, Sugar, and Force. , 2017, Developmental cell.

[82]  Cun-Yu Wang,et al.  Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma. , 2017, Cell stem cell.

[83]  Hongyan Yuan,et al.  miR-130b-3p inhibits cell invasion and migration by targeting the Notch ligand Delta-like 1 in breast carcinoma. , 2017, Gene.

[84]  Shun-Fa Yang,et al.  Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis , 2017, International journal of molecular sciences.

[85]  P. Meltzer,et al.  Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Violet A. Kiesel,et al.  Diallyl trisulfide, a chemopreventive agent from Allium vegetables, inhibits alpha-secretases in breast cancer cells. , 2017, Biochemical and biophysical research communications.

[87]  Matthew J. Brauer,et al.  Constitutive NOTCH3 Signaling Promotes the Growth of Basal Breast Cancers. , 2017, Cancer research.

[88]  Ying Tang,et al.  Antagonism of EGFR and Notch limits resistance to EGFR inhibitors and radiation by decreasing tumor-initiating cell frequency , 2017, Science Translational Medicine.

[89]  Lijun Ma,et al.  miR‐598 inhibits metastasis in colorectal cancer by suppressing JAG1/Notch2 pathway stimulating EMT , 2017, Experimental cell research.

[90]  D. Raucher,et al.  Effects of cell penetrating Notch inhibitory peptide conjugated to elastin-like polypeptide on glioblastoma cells , 2017, Journal of drug targeting.

[91]  Q. Pang,et al.  Melatonin Inhibits Glioblastoma Stem-like cells through Suppression of EZH2-NOTCH1 Signaling Axis , 2017, International journal of biological sciences.

[92]  J. Aster,et al.  The Varied Roles of Notch in Cancer. , 2017, Annual review of pathology.

[93]  Ling Yu,et al.  Cinobufagin induces apoptosis of osteosarcoma cells through inactivation of Notch signaling , 2017, European journal of pharmacology.

[94]  P. Verkade,et al.  PKCθ links proximal T cell and Notch signaling through localized regulation of the actin cytoskeleton , 2017, eLife.

[95]  G. Curigliano,et al.  Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer , 2016, Oncotarget.

[96]  J. Herz,et al.  NGP 555, a γ-secretase modulator, lowers the amyloid biomarker, Aβ42, in cerebrospinal fluid while preventing Alzheimer's disease cognitive decline in rodents , 2016, Alzheimer's & dementia.

[97]  近藤 泰介.  Notch-mediated conversion of activated T cells into stem cell memory-like T cells for adoptive immunotherapy(審査報告) , 2017 .

[98]  H. Kaufman,et al.  Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma , 2017, American Journal of Clinical Dermatology.

[99]  P. Tan,et al.  Identifying progression predictors of breast ductal carcinoma in situ , 2016, Journal of Clinical Pathology.

[100]  Kole T. Roybal,et al.  Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors , 2016, Cell.

[101]  S. Bray.  Notch signalling in context , 2016, Nature Reviews Molecular Cell Biology.

[102]  A. Neri,et al.  Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche , 2016, Oncotarget.

[103]  X. Zhang,et al.  Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. , 2016, The Journal of clinical investigation.

[104]  Zhuobin Xu,et al.  A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth , 2016, Scientific Reports.

[105]  R. Clarke,et al.  Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling , 2016, Oncotarget.

[106]  F. E. Bertrand,et al.  The Notch pathway in colorectal cancer , 2016, International journal of cancer.

[107]  J. Crabtree,et al.  Notch Signaling in Neuroendocrine Tumors , 2016, Front. Oncol..

[108]  M. Bursavich,et al.  Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon? , 2016, Journal of medicinal chemistry.

[109]  A. Sood,et al.  Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth , 2016, Molecular Cancer Therapeutics.

[110]  P. Lemotte,et al.  Characterization of activating mutations of NOTCH3 in T cell acute lymphoblastic leukemia and anti-leukemic activity of NOTCH3 inhibitory antibodies , 2016, Oncogene.

[111]  J. Grandis,et al.  Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. , 2016, Cancer research.

[112]  Rajashri R. Parab,et al.  Quinomycin A targets Notch signaling pathway in pancreatic cancer stem cells , 2015, Oncotarget.

[113]  S. Conner,et al.  Regulation of Notch Signaling Through Intracellular Transport. , 2016, International review of cell and molecular biology.

[114]  Christian A. Siltanen,et al.  Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung , 2015, Nature.

[115]  Jason V. Evans,et al.  Multivalent Forms of the Notch Ligand DLL-1 Enhance Antitumor T-cell Immunity in Lung Cancer and Improve Efficacy of EGFR-Targeted Therapy. , 2015, Cancer research.

[116]  F. Radtke,et al.  Phage Selection of Bicyclic Peptide Ligands of the Notch1 Receptor , 2015, ChemMedChem.

[117]  I. Ellis,et al.  PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance , 2015, Clinical Cancer Research.

[118]  Michael Kahn,et al.  Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update , 2015, Nature Reviews Clinical Oncology.

[119]  J. Aster,et al.  A novel Monoclonal Antibody against Notch1 Targets Leukemia-associated Mutant Notch1 and Depletes Therapy Resistant Cancer Stem Cells in Solid Tumors , 2015, Scientific Reports.

[120]  Richard Nicoletti,et al.  23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity , 2015, Molecular Cancer Therapeutics.

[121]  M. Fischer,et al.  Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency , 2015, Clinical Cancer Research.

[122]  H. Tsukamoto,et al.  NOTCH reprograms mitochondrial metabolism for proinflammatory macrophage activation. , 2015, The Journal of clinical investigation.

[123]  Hendrik Luesch,et al.  Biological targets and mechanisms of action of natural products from marine cyanobacteria. , 2015, Natural product reports.

[124]  J. Kitajewski,et al.  NOTCH decoys that selectively block DLL/NOTCH or JAG/NOTCH disrupt angiogenesis by unique mechanisms to inhibit tumor growth. , 2015, Cancer discovery.

[125]  D. Mele,et al.  The Role of Notch in the Cardiovascular System: Potential Adverse Effects of Investigational Notch Inhibitors , 2015, Front. Oncol..

[126]  B. Osborne,et al.  Non-Canonical Notch Signaling in Cancer and Immunity , 2014, Front. Oncol..

[127]  Branimir Sikic,et al.  A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors , 2014, Clinical Cancer Research.

[128]  D. Carbone,et al.  EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. , 2014, Cancer research.

[129]  Yanyu Zhao,et al.  Three-dimensional structure of human γ-secretase , 2014, Nature.

[130]  Fiorela N. Hernandez Tejada,et al.  The Challenge of Targeting Notch in Hematologic Malignancies , 2014, Front. Pediatr..

[131]  T. Golde,et al.  NOTCH1 Can Initiate NF-κB Activation via Cytosolic Interactions with Components of the T Cell Signalosome , 2014, Front. Immunol..

[132]  Yan Cui,et al.  Rescue of Notch-1 Signaling in Antigen-Specific CD8+ T Cells Overcomes Tumor-Induced T-cell Suppression and Enhances Immunotherapy in Cancer , 2014, Cancer Immunology Research.

[133]  Emma R. Andersson,et al.  Therapeutic modulation of Notch signalling — are we there yet? , 2014, Nature Reviews Drug Discovery.

[134]  A. Gurney,et al.  Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts , 2014, Leukemia.

[135]  Hugo J. Bellen,et al.  Notch Signaling , 2014, Methods in Molecular Biology.

[136]  B. Lu,et al.  Roles of PINK1, mTORC2, and mitochondria in preserving brain tumor-forming stem cells in a noncanonical Notch signaling pathway , 2013, Genes & development.

[137]  L. Miele,et al.  Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. , 2013, Cancer letters.

[138]  Javed Siddiqui,et al.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer , 2013, Nature Genetics.

[139]  K. Watabe,et al.  Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition , 2013, OncoTargets and therapy.

[140]  M. Naylor,et al.  Breast cancer stem cells , 2013, Front. Physiol..

[141]  L. Miele,et al.  Notch inhibitors for cancer treatment. , 2013, Pharmacology & therapeutics.

[142]  Lianhong Li,et al.  ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel. , 2013, The international journal of biochemistry & cell biology.

[143]  D. Berman,et al.  Modulation of Lipid Kinase PI4KIIα Activity and Lipid Raft Association of Presenilin 1 Underlies γ-Secretase Inhibition by Ginsenoside (20S)-Rg3* , 2013, The Journal of Biological Chemistry.

[144]  J. Lewin,et al.  Abstract 410: Elevated Jagged-1 and Notch-1 expression in high grade and metastatic prostate cancers. , 2013 .

[145]  D. Beer,et al.  C-Reactive Protein Downregulates TRAIL Expression in Human Peripheral Monocytes via an Egr-1–Dependent Pathway , 2013, Clinical Cancer Research.

[146]  N. Perrimon,et al.  Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. , 2013, Cancer cell.

[147]  Ian Krop,et al.  Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors , 2013, Clinical Cancer Research.

[148]  S. Pileri,et al.  The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development , 2012, The Journal of experimental medicine.

[149]  C. Perou,et al.  Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. , 2012, Cancer cell.

[150]  G. Garcia-Manero,et al.  Notch pathway activation induces neuroblastoma tumor cell growth arrest , 2012, Pediatric blood & cancer.

[151]  M. Vooijs,et al.  The role of Adams in Notch signaling. , 2012, Advances in experimental medicine and biology.

[152]  A. Iwai.  [Gamma-secretase inhibitors and modulators]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[153]  Pauliina Kronqvist,et al.  Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms , 2011, Proceedings of the National Academy of Sciences.

[154]  D. Cheresh,et al.  Tumor angiogenesis: molecular pathways and therapeutic targets , 2011, Nature Medicine.

[155]  A. Chinnaiyan,et al.  Functionally Recurrent Rearrangements of the MAST Kinase and Notch Gene Families in Breast Cancer , 2011, Nature Medicine.

[156]  D. Carbone,et al.  Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. , 2011, Cancer research.

[157]  S. Thorgeirsson,et al.  Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway , 2011, The Journal of experimental medicine.

[158]  K. Albain,et al.  Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence , 2011, British Journal of Cancer.

[159]  G. Weinmaster,et al.  Notch ligand ubiquitylation: what is it good for? , 2011, Developmental cell.

[160]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[161]  Daniel R. Dries,et al.  γ-Secretase-regulated Proteolysis of the Notch Receptor by Mitochondrial Intermediate Peptidase* , 2011, The Journal of Biological Chemistry.

[162]  A. Capobianco,et al.  Notch signalling in solid tumours: a little bit of everything but not all the time , 2011, Nature Reviews Cancer.

[163]  J. Arribas,et al.  ADAM17 (TACE) regulates TGFβ signaling through the cleavage of vasorin , 2011, Oncogene.

[164]  Hans Clevers,et al.  The cancer stem cell: premises, promises and challenges , 2011, Nature Medicine.

[165]  Yibin Kang,et al.  Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. , 2011, Cancer cell.

[166]  G. Logroscino,et al.  Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option? , 2011, Expert opinion on investigational drugs.

[167]  J. Corbo,et al.  Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. , 2011, The Journal of clinical investigation.

[168]  R. Clarke,et al.  Breast cancer stem cells: something out of notching? , 2010, Cancer research.

[169]  A. Verkhratsky,et al.  An intelligent sarco-endoplasmic reticulum Ca2+ store: release and leak channels have differential access to a concealed Ca2+ pool. , 2010, Cell calcium.

[170]  M. Shimada,et al.  Notch2 Signaling Is Required for Potent Antitumor Immunity In Vivo , 2010, The Journal of Immunology.

[171]  Thijs J. Hagenbeek,et al.  Therapeutic antibody targeting of individual Notch receptors , 2010, Nature.

[172]  L. R. Perumalsamy,et al.  Notch-activated signaling cascade interacts with mitochondrial remodeling proteins to regulate cell survival , 2010, Proceedings of the National Academy of Sciences of the United States of America.

[173]  T. Yeatman,et al.  Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. , 2010, Cancer research.

[174]  W. Leonard,et al.  Atopic Dermatitis-Like Disease and Associated Lethal Myeloproliferative Disorder Arise from Loss of Notch Signaling in the Murine Skin , 2010, PloS one.

[175]  S. Lipkin,et al.  NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. , 2010, Cancer research.

[176]  Minhong Yan,et al.  Chronic DLL4 blockade induces vascular neoplasms , 2010, Nature.

[177]  K. Ross,et al.  Characterization of Notch1 Antibodies That Inhibit Signaling of Both Normal and Mutated Notch1 Receptors , 2010, PloS one.

[178]  R. Clarke,et al.  Tumor and Stem Cell Biology Cancer Research Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch 4 Receptor , 2010 .

[179]  S. Liang,et al.  Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway , 2010, Oncogene.

[180]  Raymond E. Moellering,et al.  Direct inhibition of the NOTCH transcription factor complex , 2010, Nature.

[181]  G. Pelosi,et al.  Alterations of the Notch pathway in lung cancer , 2009, Proceedings of the National Academy of Sciences.

[182]  Raphael Kopan,et al.  The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.

[183]  T. Golde,et al.  Notch Regulates Cytolytic Effector Function in CD8+ T Cells1 , 2009, Journal of Immunology.

[184]  H. Dombret,et al.  NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. , 2009, Blood.

[185]  P. Tsao,et al.  γ-Secretase Activation of Notch Signaling Regulates the Balance of Proximal and Distal Fates in Progenitor Cells of the Developing Lung* , 2008, Journal of Biological Chemistry.

[186]  U. Lendahl,et al.  Notch-1 associates with IKKα and regulates IKK activity in cervical cancer cells , 2008, Oncogene.

[187]  S. Sone,et al.  Notch2 integrates signaling by the transcription factors RBP-J and CREB1 to promote T cell cytotoxicity , 2008, Nature Immunology.

[188]  G. Thurston,et al.  VEGF and Delta-Notch: interacting signalling pathways in tumour angiogenesis , 2008, British Journal of Cancer.

[189]  Frank J. Slack,et al.  MicroRNAs and cancer: An overview , 2008, Cell cycle.

[190]  Hans Clevers,et al.  Loss of intestinal crypt progenitor cells owing to inactivation of both Notch1 and Notch2 is accompanied by derepression of CDK inhibitors p27Kip1 and p57Kip2 , 2008, EMBO reports.

[191]  R. Arceci.  Notch Pathway Inhibition Depletes Stem-like Cells and Blocks Engraftment in Embryonal Brain Tumors , 2008 .

[192]  F. Radtke,et al.  Notch and cancer: a double-edged sword , 2008, Cellular and Molecular Life Sciences.

[193]  A. Gazdar,et al.  Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. , 2007, Cancer research.

[194]  J. Aster,et al.  Structural basis for autoinhibition of Notch , 2007, Nature Structural &Molecular Biology.

[195]  F. Real,et al.  Nuclear IKK activity leads to dysregulated Notch-dependent gene expression in colorectal cancer , 2007, Proceedings of the National Academy of Sciences.

[196]  Minhong Yan,et al.  Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis , 2006, Nature.

[197]  Gavin Thurston,et al.  Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis , 2006, Nature.

[198]  Jian Wang,et al.  Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. , 2006, Genes & development.

[199]  I. Screpanti,et al.  Notch3 and pre‐TCR interaction unveils distinct NF‐κB pathways in T‐cell development and leukemia , 2006, The EMBO journal.

[200]  J. Boulter,et al.  The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands , 2005, The Journal of cell biology.

[201]  H. Avet-Loiseau,et al.  Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. , 2004, Blood.

[202]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[203]  S. Varambally,et al.  JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence , 2004, Cancer Research.

[204]  A. Sarin,et al.  The Anti-apoptotic Effect of Notch-1 Requires p56lck-dependent, Akt/PKB-mediated Signaling in T Cells* , 2004, Journal of Biological Chemistry.

[205]  K. Raj,et al.  The role of Notch in tumorigenesis: oncogene or tumour suppressor? , 2003, Nature Reviews Cancer.

[206]  Freddy Radtke,et al.  Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation , 2001, The EMBO journal.

[207]  J. Minna,et al.  Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. , 2000, Journal of the National Cancer Institute.

[208]  Yang Wang,et al.  Fringe is a glycosyltransferase that modifies Notch , 2000, Nature.

[209]  S. Cohen,et al.  Glycosyltransferase activity of Fringe modulates Notch–Delta interactions , 2000, Nature.

[210]  F. Watt,et al.  Stimulation of human epidermal differentiation by Delta–Notch signalling at the boundaries of stem-cell clusters , 2000, Current Biology.

[211]  J. Sklar,et al.  TAN-1, the human homolog of the Drosophila Notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms , 1991, Cell.

[212]  I. Greenwald,et al.  glp-1 and lin-12, genes implicated in distinct cell-cell interactions in C. elegans, encode similar transmembrane proteins , 1989, Cell.

[213]  Kathleen Weston,et al.  The Caenorhabditis elegans lin-12 gene encodes a transmembrane protein with overall similarity to Drosophila Notch , 1988, Nature.

[214]  S. Artavanis-Tsakonas,et al.  Nucleotide sequence from the neurogenic locus Notch implies a gene product that shares homology with proteins containing EGF-like repeats , 1985, Cell.

[215]  S. Artavanis-Tsakonas,et al.  Molecular cloning of Notch, a locus affecting neurogenesis in Drosophila melanogaster. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[216]  R. Punnett,et al.  The Theory of the Gene , 1926, Nature.